

2020 Financial Statements

These figures are extracted from the complete annual report 2020 of Stichting International Kidney Cancer Coalition in Ouder-Amstel as determined by the Board on October 29, 2021.

This annual report has been provided with an unqualified auditor's report, by Van Hoesel/De Blaey Accountancy B.V. on October 29, 2021.

Anne Wilson

Anne Wilson
Secretary/Treasurer

IKCC
Board Members

Mgmt. Services
Legal Entity

The Global Collaboration Of National Patient Groups Supporting Those Affected By Kidney Cancer.

R. Giles (NL) * B. Lewis (USA) * B. Eberhardt (DE) *

M. Jewett (CA) * E. Jonasch (USA) * A. Wilson (AU) * R. Woodward (UK)

Operations Manager: Julia Black (UK) julia@ikcc.org

Foundation, registered in the Netherlands: Stichting Intl. Kidney Cancer Coalition, Reg.No. KvK 62070665

2. FINANCIAL STATEMENTS

Stichting International Kidney Cancer Coalition

2.1 Balance sheet as of 31 December 2020

(After result appropriation)

ASSETS	31 December 2020		31 December 2019	
	€	€	€	€
Current assets				
<i>Receivables</i>				
Other prepayments and accrued income	<u>88.174</u>	88.174	<u>67.210</u>	67.210
<i>Cash at bank and in hand</i>		868.061		667.995
Total assets		<u><u>956.235</u></u>		<u><u>735.205</u></u>

Stichting International Kidney Cancer Coalition

2.1 Balance sheet as of 31 December 2020

(After result appropriation)

LIABILITIES	31 December 2020		31 December 2019	
	€	€	€	€
Equity capital				
Restricted reserves	526.000		365.000	
Unrestricted reserves	256.201		206.700	
		782.201		571.700
Current liabilities				
Accounts payable	17.868		38.121	
Accrued liabilities	156.166		125.384	
		174.034		163.505
Total liabilities		956.235		735.205

Stichting International Kidney Cancer Coalition

2.2 Statement of income and expenditure 2020

	2020		2019	
	€	€	€	€
Income		663.618		651.858
Expenditure		453.117		505.867
Operating surplus		<u>210.501</u>		<u>145.991</u>

The amendment of reserves is divided as follows:

Restricted reserves World Kidney Cancer Day	113.473-	-
Restricted reserves Global Kidney Cancer Summit	33.424-	-
Restricted reserves PAG Incubator	-	-
Restricted reserves COVID-19	-	-
Restricted reserves Dashboard Project	2.637-	-
Restricted reserves Global Patient Survey Communications	45.952-	-
Restricted reserves Clinical Trial Retention Problems	-	-
Restricted reserves Decision Aid: Clinical Trials Basics	-	-
The addition to the unrestricted reserves	<u>405.987</u>	<u>145.991</u>
Operating surplus	<u>210.501</u>	<u>145.991</u>

2.3 Cash flow statement 2020

The cash flow statement has been prepared according to the indirect method.

	2020		2019	
	€	€	€	€
Cash flow from operating activities				
Operating result		210.501		145.991
Change in working capital:				
Receivables	20.964-		65.994-	
Current liabilities (except debts to credit institutions)	10.529		63.121	
		<u>10.435-</u>		<u>2.873-</u>
Cash flow from IKCC operations		200.066		143.118
Cash flow from operating activities		<u>200.066</u>		<u>143.118</u>
Movements in cash		<u>200.066</u>		<u>143.118</u>
Notes to the cash resources				
Total by 1 January 2020		667.995		524.877
Movements in cash		<u>200.066</u>		<u>143.118</u>
Total by 31 December		<u>868.061</u>		<u>667.995</u>

2.4 Notes to the financial statements

General notes

Activities

The activities of Stichting International Kidney Cancer Coalition, having its registered office at Ouder-Amstel primarily consist of:

- The International Kidney Cancer Coalition (IKCC) is an independent international network of patient organisations that focus exclusively, or include a specific focus, on kidney cancer. It is legally incorporated as a Foundation in the Netherlands. The organisation was born from a very strong desire among various national kidney cancer patient groups to network, cooperate and share materials, knowledge and experiences. IKCC is governed by a volunteer Board of Directors with members from a minimum of four countries.

The actual activities are carried out at , Ouder-Amstel.

Registered office, legal form and registration number at the chamber of commerce

Stichting International Kidney Cancer Coalition, B31 has been registered at the Chamber of Commerce under file number 62070665.

Estimates

In applying the principles and policies for drawing up the financial statements, the management of the IKCC makes different estimates and judgments that may be essential to the amounts disclosed in the financial statements. If it is necessary in order to provide the transparency required under art. 362, sub 1, book 2 of the Dutch Civil Code the nature of these estimates and judgments, including related assumptions, is disclosed in the Notes to the relevant financial statement item.

General accounting policies

General

The financial statements are drawn up in accordance with the Richtlijnen voor de Jaarverslaggeving C1 Kleine Organisaties-zonder-winststreven (RJK C1).

The valuation of assets and liabilities and the determination of the result are based on historical costs. Unless stated otherwise in the respective basis for the specific balance sheet item, the assets and liabilities are valued according to the cost-price model.

Income and expenditure are allocated to the year to which they are related. Results are only included to the extent they have been achieved on the balance sheet date. Liabilities and potential losses originating before the end of the reporting year are taken into account if they are known before the preparation of the annual accounts.

Comparison with previous year

The valuation principles and method of determining the result are the same as those used in the previous year, with the exception of the changes in accounting policies as set out in the relevant sections.

Foreign currency

Functional currency

Items included in the financial statements of the Foundation are valued with due regard for the currency in the economic environment in which the Foundation carries out most of its activities (the functional currency). The financial statements are denominated in euros; this is both the functional currency and presentation currency of the Foundation.

2.4 Notes to the financial statements

Transactions, receivables and liabilities

Transactions in foreign currencies are stated in the financial statements at the exchange rate of the functional currency on the transaction date.

Monetary assets and liabilities in foreign currencies are converted to the closing rate of the functional currency on the balance sheet date. The translation differences resulting from settlement and conversion are credited or charged to the income statement, unless hedge-accounting is applied.

Non-monetary assets valued at historical cost in a foreign currency are converted at the exchange rate on the transaction date.

ACCOUNTING POLICIES APPLIED TO THE VALUATION OF ASSETS AND LIABILITIES

Accounts receivable

The receivables are initially recognised at the fair value and subsequently valued at amortised costs. The fair value and amortised cost are equal to the nominal value. Provisions deemed necessary for the risk of bad debts are deducted. The provisions are determined based on individual assessment of the receivables.

Cash at banks and in hand

Cash at banks and in hand represent cash in hand, bank balances and deposits with terms of less than twelve months. Overdrafts at banks are recognised as part of debts to lending institutions under current liabilities. Cash at banks and in hand is carried at nominal value.

Current liabilities

On initial recognition current liabilities are recognised at fair value. After initial recognition current liabilities are recognised at the amortised cost price, being the amount received, taking into account premiums or discounts, less transaction costs. This usually is the nominal value.

Reserves

Unrestricted reserves

The Foundation has unrestricted reserves, which may be freely spent within the statutory objectives of the organisation. Amendments on the unrestricted reserves are done through the results allocation of the statement of income and expenditure.

Restricted Reserves

The Foundation has Restricted reserves, which have a more limited designation than the Unrestricted Reserves. The limitation of the reserves is imposed by the Board of Directors. Amendments on the Restricted reserves are done through the result allocation of the statement of income and expenditure.

2.4 Notes to the financial statements

PRINCIPLES FOR THE DETERMINATION OF THE RESULT

General

The surplus or deficit is determined as the difference between the total income and total expenses of the year to which they relate.

Income

The income of the Foundation is recorded and recognized in the period in which the income has been effectuated. The effectuation is determined based on the sponsorship period or the realization of events.

Expense

The expenses of the Foundation are determined on a historical basis and are attributed to the reporting year to which they relate.

PRINCIPLES FOR THE PREPARATION OF THE CASH-FLOW STATEMENT

Accounting policies for the cash flow statement

The cash flow statement is prepared according to the indirect method. The cash items disclosed in the cash flow statement comprise cash at bank and in hand. Cash flow denominated in foreign currencies have been translated at average estimated exchange rates.

Interest paid and received, dividends received and income taxes are included in cash from operating activities.

2.5 Notes to the balance sheet

ASSETS

CURRENT ASSETS

Receivables

	<u>31-12-2020</u>	<u>31-12-2019</u>
	€	€
Other prepayments and accrued income		
Costs paid up front	33.174	67.210
Amounts receivable	<u>55.000</u>	<u>-</u>
	<u><u>88.174</u></u>	<u><u>67.210</u></u>
 Cash at bank and in hand		
ING payment account	6.875	18.357
ING reserve operating account	150.185	150.138
ING US Dollar account	711.059	499.585
Creditcard	58-	85-
	<u><u>868.061</u></u>	<u><u>667.995</u></u>

2.5 Notes to the balance sheet

LIABILITIES

Foundation's capital

	2020	2019
	€	€
Restricted reserves World Kidney Cancer Day		
Value as of 1 January	120.000	-
Utilization	113.473-	-
From unrestricted reserves	113.473	120.000
Value as of 31 December	<u>120.000</u>	<u>120.000</u>

	2020	2019
	€	€
Restricted reserves Global Kidney Cancer Summit		
Value as of 1 January	116.000	-
Utilization	33.424-	-
From unrestricted reserves	33.424	116.000
Value as of 31 December	<u>116.000</u>	<u>116.000</u>

	2020	2019
	€	€
Restricted reserves PAG Incubator		
Value as of 1 January	-	-
Utilization	-	-
From unrestricted reserves	100.000	-
Value as of 31 December	<u>100.000</u>	<u>-</u>

	2020	2019
	€	€
Restricted reserves COVID-19		
Value as of 1 January	-	-
Utilization	-	-
From unrestricted reserves	45.000	-
Value as of 31 December	<u>45.000</u>	<u>-</u>

	2020	2019
	€	€
Restricted reserves Dashboard Project		
Value as of 1 January	44.000	-
Utilization	2.637-	-
From unrestricted reserves	2.637	44.000
Value as of 31 December	<u>44.000</u>	<u>44.000</u>

2.5 Notes to the balance sheet

	2020	2019
	€	€
Restricted reserves Global Patient Survey Communications		
Value as of 1 January	85.000	-
Utilization	45.952-	-
From unrestricted reserves	2.952	85.000
Value as of 31 December	<u>42.000</u>	<u>85.000</u>
	2020	2019
	€	€
Restricted reserves Clinical Trial Retention Problems		
Value as of 1 January	-	-
Utilization	-	-
From unrestricted reserves	39.000	-
Value as of 31 December	<u>39.000</u>	<u>-</u>
	2020	2019
	€	€
Restricted reserves Decision Aid: Clinical Trials Basics		
Value as of 1 January	-	-
Utilization	-	-
From unrestricted reserves	20.000	-
Value as of 31 December	<u>20.000</u>	<u>-</u>
	2020	2019
	€	€
Unrestricted reserves		
Value as of 1 January	206.700	425.709
To restricted reserves	356.486-	365.000-
Operating result	405.987	145.991
Value as of 31 December	<u>256.201</u>	<u>206.700</u>

2.5 Notes to the balance sheet

CURRENT LIABILITIES

	<u>31-12-2020</u>	<u>31-12-2019</u>
	€	€
Accounts payable		
Creditors	<u>17.868</u>	<u>38.121</u>
Accrued liabilities		
Amounts received in advance	141.255	88.742
Payable costs	<u>14.911</u>	<u>36.642</u>
	<u>156.166</u>	<u>125.384</u>

Stichting International Kidney Cancer Coalition

2.6 Notes to the profit and loss account

	<u>2020</u>	<u>2019</u>
	€	€
Income		
Sustaining partnerships	179.060	141.333
Projects	484.558	510.525
	<u>663.618</u>	<u>651.858</u>
Expenditure		
Objective 1: To strenghten the capacity of current and emerging affiliates in their support for patients with Kidney Cancer.	77.384	111.671
Objective 2: To advocate for access to best care	116.698	88.126
Objective 3: To increase awareness of Kidney Cancer globally	157.433	163.228
Objective 4: To be an authority in the provision of Kidney Cancer information	61.494	72.249
Objective 5: To foster projects promoting the voice of Kidney Cancer patients in research activities worldwide	40.108	70.593
	<u>453.117</u>	<u>505.867</u>